Novasoy vs Placebo: Number of Participants With ApoE4 Allele
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.336 | 0.664 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.455 | 0.298 | 0.62 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0455 | -0.187 | 0.272 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.661 | 1.83 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.2 | 0.453 | 3.18 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Novasoy than on Placebo | 22 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Novasoy | 100mg/day soy isoflavones~Novasoy: 100mg/day soy isoflavones | 16 | 32 | OG001 | ClinicalTrials.gov |
| Group 2 | Placebo | 100mg/day matching placebo~Placebo: 100mg/day matching placebo | 15 | 33 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With ApoE4 Allele | ClinicalTrials.gov |
| Description | The epsilon-4 allele of the apolipoprotein E gene (APOE4) has been consistently associated with a greater risk of Alzheimer's disease (AD) as well as an earlier onset of AD.~Determination of apolipoprotein E (APOE) genotype was performed on a non-fasting blood sample collected at Baseline, using standard Polymerase chain reaction (PCR) and DNA sequencing techniques in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. DNA extracted from whole blood was amplified by PCR using specific primers for the ApoE gene and the DNA then sequenced and analyzed for genotype using the FinchTV program (Version 1.3; Geospiza, Inc.) | ClinicalTrials.gov |
| Time frame | Baseline | ClinicalTrials.gov |
| Population | Older adults with Alzheimer's disease | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Alzheimer's Disease: Potential Benefit of Isoflavones | ClinicalTrials.gov |
| NCT number | NCT00205179 | ClinicalTrials.gov |
| Phases | PHASE2 | ClinicalTrials.gov |
| Conditions | Alzheimer's Disease | ClinicalTrials.gov |
| Interventions | Novasoy, Placebo | ClinicalTrials.gov |
| Lead sponsor | University of Wisconsin, Madison | ClinicalTrials.gov |
| Results first posted | 2020-01-22 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00205179?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.